Literature DB >> 26244882

Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis.

Gwan Gyu Song1, Young Ho Seo1, Jae-Hoon Kim1, Sung Jae Choi1, Jong Dae Ji1, Young Ho Lee1.   

Abstract

AIM: The aim of this study is to investigate whether TNF-α polymorphisms are associated with the responsiveness to anti-TNF-α therapy in patients with spondyloarthropathy, psoriasis, and Crohn's disease.
METHODS: We conducted a meta-analysis on the association between the TNF-α polymorphisms and responsiveness of patients.
RESULTS: The meta-analysis indicated an association between the TNF-α -308 G allele (OR = 2.005; 95% CI: 1.417-2.838; p = 8.6 × 10(-5)), TNF-α -238 G allele (OR = 2.196; 95% CI: 1161-4.154; p = 0.016), and TNF-α -857 C allele (OR = 1.779; 95% CI: 1.130-2.802; p = 0.013) and response to TNF-α blockers in Caucasians.
CONCLUSION: Individuals carrying the TNF-α -308 G, -238 G, or -857 C common alleles show better responses to TNF-α blockers than those with minor alleles in Caucasians.

Entities:  

Keywords:  TNF-α inhibitors; TNF-α polymorphism; psoriasis; responsiveness; spondyloarthropathy

Mesh:

Substances:

Year:  2015        PMID: 26244882     DOI: 10.2217/pgs.15.90

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  20 in total

Review 1.  Pharmacogenetic biomarkers of response in Crohn's disease.

Authors:  T M Linares-Pineda; M Cañadas-Garre; A Sánchez-Pozo; M Á Calleja-Hernández
Journal:  Pharmacogenomics J       Date:  2017-06-20       Impact factor: 3.550

2.  Profile of Tumour Necrosis Factor Alpha -308 G/A Gene Polymorphism in Psoriatic Patients in Karnataka, India.

Authors:  Deepa Rajesh; Chaitra Chowdappa; Rajesh Gurumurthy; A V Moideen Kutty; Sharath Balakrishna
Journal:  J Clin Diagn Res       Date:  2017-02-01

3.  Fast clearance of anti-TNFα agents unrelated to antidrug antibodies: a case report.

Authors:  Stefania Cheli; Valeria Cozzi; Dario Cattaneo; Lorenzo Norsa; Costantino De Giacomo; Emilio Clementi; Chiara Moretti
Journal:  Eur J Clin Pharmacol       Date:  2022-02-18       Impact factor: 2.953

4.  Association of polymorphisms in promoter region of TNF-α -238 and -308 with clinical outcomes in patients with immune-mediated inflammatory diseases on anti-TNF therapy.

Authors:  Marijana Miler; Nora Nikolac Gabaj; Ivana Ćelap; Simeon Grazio; Vedran Tomašić; Alen Bišćanin; Joško Mitrović; Lovorka Đerek; Jadranka Morović-Vergles; Nada Vrkić; Mario Štefanović
Journal:  Rheumatol Int       Date:  2021-10-08       Impact factor: 2.631

5.  Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients With Inflammatory Bowel Disease.

Authors:  Ming-Hsi Wang; Jessica J Friton; Laura E Raffals; Jonathan A Leighton; Shabana F Pasha; Michael F Picco; Kelly C Cushing; Kelly Monroe; Billy D Nix; Rodney D Newberry; William A Faubion
Journal:  J Crohns Colitis       Date:  2019-08-14       Impact factor: 9.071

Review 6.  Treatment Approaches to Moderate to Severe Psoriasis.

Authors:  Paolo Gisondi; Micol Del Giglio; Giampiero Girolomoni
Journal:  Int J Mol Sci       Date:  2017-11-16       Impact factor: 5.923

7.  Genetics in TNF-TNFR pathway: A complex network causing spondyloarthritis and conditioning response to anti-TNFα therapy.

Authors:  Ada Aita; Daniela Basso; Roberta Ramonda; Stefania Moz; Mariagrazia Lorenzin; Filippo Navaglia; Carlo-Federico Zambon; Andrea Padoan; Mario Plebani; Leonardo Punzi
Journal:  PLoS One       Date:  2018-03-26       Impact factor: 3.240

Review 8.  An overview of meta-analysis for clinicians.

Authors:  Young Ho Lee
Journal:  Korean J Intern Med       Date:  2017-12-28       Impact factor: 2.884

Review 9.  TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis.

Authors:  Jing Liu; Zheng Dong; Qi Zhu; Dongyi He; Yanyun Ma; Aiping Du; Fan He; Dongbao Zhao; Xia Xu; Hui Zhang; Li Jin; Jiucun Wang
Journal:  Sci Rep       Date:  2016-08-31       Impact factor: 4.379

10.  Role of TNFRSF1A and TNFRSF1B polymorphisms in susceptibility, severity, and therapeutic efficacy of etanercept in human leukocyte antigen-B27-positive Chinese Han patients with ankylosing spondylitis.

Authors:  Wang Xing-Rong; Xu Sheng-Qian; Liu Wen; Qi Shan; Pan Fa-Ming; Xu Jian-Hua
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.